Prior Authorization Neurontin (gabapentin) 2016
|
|
|
- Tracey Patience Small
- 6 years ago
- Views:
Transcription
1 Drugs Requiring Prior Authorization Label Name GCN GABAPENTIN 100 MG CAPSULE GABAPENTIN 300 MG CAPSULE GABAPENTIN 400 MG CAPSULE GABAPENTIN 250 MG/5 ML SOLN GABAPENTIN 600 MG TABLET GABAPENTIN 800 MG TABLET NEURONTIN 100 MG CAPSULE NEURONTIN 300 MG CAPSULE NEURONTIN 400 MG CAPSULE NEURONTIN 250 MG/5 ML SOLN NEURONTIN 600 MG TABLET NEURONTIN 800 MG TABLET Clinical Edit Criteria Logic 1. Is the dose less than or equal to 1,400 mg per day? Yes (Approve 365 Days) No (Go to #2) 2. Does the client have a diagnosis of Chronic Kidney Disease in the last 365 days? Yes (Deny) No (Approve 365 Days)
2 Clinical Edit Criteria Logic Diagram Step 1: Is the dose less than or equal to 1,400 mg per day? Yes Approve for 365 days No Step 2: Does the client have a diagnosis of Chronic Kidney Disease in the last 365 days? Yes Deny No Approve for 365 Days
3 Clinical Edit Criteria Supporting Tables ICD-9 Code Description Step 2 (Diagnosis of Chronic Kidney Disease) Required Diagnosis: 1 Look Back Timeframe: 365 Days 403 HYPERTENSIVE CHRONIC KIDNEY DISEASE 4030 MALIGNANT HYPERTENSIVE KIDNEY DISEASE HYPERTENSIVE CHRONIC KIDNEY DISEASE, MALIGNANT, WITH CHRONIC KIDNEY DISEASE STAGE I THROUGH STAGE IV, OR UNSPECIFIED HYPERTENSIVE CHRONIC KIDNEY DISEASE, MALIGNANT, WITH 4031 BENIGN HYPERTENSIVE KIDNEY DISEASE HYPERTENSIVE CHRONIC KIDNEY DISEASE, BENIGN, WITH CHRONIC KIDNEY DISEASE STAGE I THROUGH STAGE IV, OR UNSPECIFIED HYPERTENSIVE CHRONIC KIDNEY DISEASE, BENIGN, WITH CHRONIC KIDNEY DISEASE STAGE V OR END STAGE RENAL DISEASE 4039 UNSPECIFIED CHRONIC KIDNEY DISEASE 404 HYPERTENSIVE HEART AND CHRONIC KIDNEY DISEASE 4040 MALIGNANT HYPERTENSIVE HEART AND KIDNEY DISEASE HYPERTENSIVE HEART AND CHRONIC KIDENY DISEASE, MALIGNANT WITHOUT HEART FAILURE AND WITH CHRONIC KIDNEY DISEASE STAGE I THROUGH STAGE IV, OR UNSPECIFIED HYPERTENSIVE HEART AND CHRONIC KIDENY DISEASE, MALIGNANT WITH HEART FAILURE AND WITH CHRONIC KIDNEY DISEASE STAGE V HYPERTENSIVE CHRONIC KIDNEY DISEASE, MALIGNANT, WITHOUT HYPERTENSIVE CHRONIC KIDNEY DISEASE, MALIGNANT, WITH 4041 BENIGN HYPERTENSIVE HEART AND KIDNEY DISEASE WITHOUT HEART FAILURE AND WITH CHRONIC KIDNEY STAGE I THROUGH STAGE IV, OR UNSPECIFIED WITH HEART FAILURE AND WITH CHRONIC KIDNEY STAGE I THROUGH STAGE IV, OR UNSPECIFIED WITHOUT HEART FAILURE AND WITH CHRONIC KIDNEY STAGE V OR END STAGE RENAL DISEASE
4 40413 WITH HEART FAILURE AND WITH CHRONIC KIDNEY STAGE V OR END STAGE RENAL DISEASE 4049 UNSPECIFIED HYPERTENSIVE HEART AND KIDNEY DISEASE 582 CHRONIC 5820 CHR PROLIFERAT NEPHRITIS 5821 CHR MEMBRANOUS NEPHRITIS 5822 CHR MEMBRANOPROLIF NEPHRITIS 5824 CHR RAPID PROGR NEPHRIT 5828 CHRONIC WITH OTHER SPECIFIED PATHOOLOGICAL LESION IN KIDNEY CHR NEPHRITIS IN OTH DIS CHR NEPHRITIS NEC 5829 CHR NEPHRITIS NOS 585 CHRONIC RENAL FAILURE 5851 CHRONIC KIDNEY DISEASE, STAGE I 5852 CHRONIC KIDNEY DISEASE, STAGE II (MILD) 5853 CHRONIC KIDNEY DISEASE, STAGE III (MODERATE) 5854 CHRONIC KIDNEY DISEASE, STAGE IV (SEVERE) 5855 CHRONIC KIDNEY DISEASE, STAGE V 5856 END STAGE RENAL DISEASE 5859 CHRONIC KIDNEY DISEASE, UNSPECIFIED ICD-10 Code I120 I129 I130 I1310 I1311 I132 N030 Description HYPERTENSIVE CHRONIC KIDNEY DISEASE WITH STAGE 5 CHRONIC KIDNEY DISEASE OR END STAGE RENAL DISEASE HYPERTENSIVE CHRONIC KIDNEY DISEASE WITH STAGE 1 THROUGH STAGE 4 CHRONIC KIDNEY DISEASE, OR UNSPECIFIED CHRONIC KIDNEY DISEASE HYPERTENSIVE HEART AND CHRONIC KIDNEY DISEASE WITH HEART FAILURE AND STAGE 1 THROUGH STAGE 4 CHRONIC KIDNEY DISEASE, OR UNSPECIFIED CHRONIC KIDNEY DISEASE HYPERTENSIVE HEART AND CHRONIC KIDNEY DISEASE WITHOUT HEART FAILURE, WITH STAGE 1 THROUGH STAGE 4 CHRONIC KIDNEY DISEASE, OR UNSPECIFIED CHRONIC KIDNEY DISEASE HYPERTENSIVE HEART AND CHRONIC KIDNEY DISEASE WITHOUT HEART FAILURE, WITH STAGE 5 CHRONIC KIDNEY DISEASE, OR END STAGE RENAL DISEASE HYPERTENSIVE HEART AND CHRONIC KIDNEY DISEASE WITH HEART FAILURE AND WITH STAGE 5 CHRONIC KIDNEY DISEASE, OR END STAGE RENAL DISEASE CHRONIC NEPHRITIC SYNDROME WITH MINOR GLOMERULAR ABNORMALITY
5 N031 N032 N033 N034 N035 N036 N037 N038 N039 CHRONIC NEPHRITIC SYNDROME WITH FOCAL AND SEGMENTAL GLOMERULAR LESIONS CHRONIC NEPHRITIC SYNDROME WITH DIFFUSE MEMBRANOUS CHRONIC NEPHRITIC SYNDROME WITH DIFFUSE MESANGIAL PROLIFERATIVE CHRONIC NEPHRITIC SYNDROME WITH DIFFUSE ENDOCAPILLARY PROLIFERATIVE CHRONIC NEPHRITIC SYNDROME WITH DIFFUSE MESANGIOCAPILLARY CHRONIC NEPHRITIC SYNDROME WITH DENSE DEPOSIT DISEASE CHRONIC NEPHRITIC SYNDROME WITH DIFFUSE CRESCENTIC CHRONIC NEPHRITIC SYNDROME WITH OTHER MORPHOLOGIC CHANGES CHRONIC NEPHRITIC SYNDROME WITH UNSPECIFIED MORPHOLOGIC CHANGES N181 CHRONIC KIDNEY DISEASE, STAGE 1 N182 N183 N184 CHRONIC KIDNEY DISEASE, STAGE 2 (MILD) CHRONIC KIDNEY DISEASE, STAGE 3 (MODERATE) CHRONIC KIDNEY DISEASE, STAGE 4 (SEVERE) N185 CHRONIC KIDNEY DISEASE, STAGE 5 N186 N189 END STAGE RENAL DISEASE CHRONIC KIDNEY DISEASE, UNSPECIFIED References 1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc., updated January Available at ICD-9-CM Diagnosis Codes, Volume 1, Available at Accessed on August 14, ICD-10-CM Diagnosis Codes Available at Accessed on April 3, American Medical Association data files ICD-9-CM Diagnosis Codes. Available at 5. American Medical Association data files ICD-10-CM Diagnosis Codes. Available at Publication History Publication Date Notes 04/17/2012 Initial Publication 07/20/ Added ICD-10 Codes Updated Dates
Texas Prior Authorization Program Clinical Edit Criteria
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Thiazolidinediones Clinical Edit Information Included in this Document Thiazolidinediones Drugs requiring prior authorization: the
Texas Prior Authorization Program Clinical Criteria
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Clinical Criteria Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
Texas Prior Authorization Program Clinical Edit Criteria
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Xifaxan 200mg Drugs requiring prior authorization: the list of drugs requiring
Amitiza (Lubiprostone)
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
Texas Prior Authorization Program Clinical Edit Criteria
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
Prior Authorization Flexeril/Amrix (cyclobenzaprine) 2017
Drugs Requiring Prior Authorization Label Name GCN AMRIX ER 15 MG CAPSULE 97959 AMRIX ER 30 MG CAPSULE 97960 CYCLOBENZAPRINE 10 MG TABLET 18020 CYCLOBENZAPRINE 5 MG TABLET 12805 CYCLOBENZAPRINE 7.5 MG
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Clinical Criteria Information Included in this Document DPP-4 Inhibitor Criteria A: Alogliptin 6.25mg, Januvia 25mg, Nesina 6.25mg, Onglyza
Texas Prior Authorization Program Clinical Edit Criteria
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Provigil (Modafinil) Drugs requiring prior authorization: the list of drugs
Texas Prior Authorization Program Clinical Edit Criteria
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document - Oral Drugs requiring prior authorization: the list of drugs requiring prior
Fentanyl Agents Clinical Edit Criteria
Fentanyl Agents Clinical Edit Criteria Drug/Drug Class: Fentanyl Agents Superior HealthPlan follows the guidance of the Texas Vendor Drug Program (VDP) for all clinical edit criteria. Superior has adjusted
Sitagliptin (Januvia)
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document 25mg Drugs requiring prior authorization: the list of drugs requiring prior
Texas Prior Authorization Program Clinical Criteria
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Clinical Information Included in this Document Xifaxan 200mg Drugs requiring prior authorization: the list of drugs requiring prior authorization
Texas Prior Authorization Program Clinical Edit Criteria
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
Hypoglycemics, Lantus Insulin
Texas Prior Authorization Program PDL Edit Criteria Drug/Drug Class Hypoglycemics, Lantus Insulin Information Included in this Document Hypoglycemics, Lantus Insulin Drugs requiring prior authorization:
List of Chronic Conditions under the Community Health Assist Scheme (CHAS)
List of Chronic s under the Community Health Assist Scheme (CHAS) Chronic Diabetes Mellitus Hypertension Lipid Disorders Stroke Asthma Chronic Obstructive Pulmonary Disease (COPD) Schizophrenia Major Depression
Methylnaltrexone Bromide (Relistor)
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Combination Agents
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Combination Agents This criteria was recommended for review by an MCO to ensure appropriate
Diclofenac 3% Gel, Diclofenac 1.5% and 2% Topical Solution
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class, Diclofenac 1.5% and 2% Topical Solution This criteria was recommended for review by an MCO to ensure appropriate and safe utilization
Flexeril/Amrix (Cyclobenzaprine)
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
The new ERA-EDTA PRDs UK Renal SNOMED CT subset TheProject
The new ERA-EDTA PRDs UK Renal SNOMED CT subset TheProject Keith Simpson UKRR Advisor keith.simpson@nhs.net Thanks to ERA-EDTA Registry: Kitty Jager Managing Dir and members of the Coding and Terminology
Texas Prior Authorization Program Clinical Criteria. This criteria was recommended for review by an MCO to ensure appropriate and safe utilization.
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class This criteria was recommended for review by an MCO to ensure appropriate and safe utilization. Clinical Information Included in this
Victoza (Liraglutide) Solution for Injection
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
Flexeril/Amrix (Cyclobenzaprine) Clinical Edit Criteria
Flexeril/Amrix (Cyclobenzaprine) Clinical Edit Criteria Drug/Drug Class: Flexeril/Amrix (Cyclobenzaprine) Superior HealthPlan follows the guidance of the Texas Vendor Drug Program (VDP) for all clinical
Byetta (Exenatide Injection)
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
COMPREHENSIVE DIABETES CARE
COMPREHENSIVE DIABETES CARE APPLICATIONS OBJECTIVE Purpose of Measure: ELIGIBLE POPULATION Which members are included? STANDARD OF CARE What screening should be done? HbA1c Eye Exam Blood Pressure Nephropathy
Injectable Agents for the Treatment of Pulmonary Arterial Hypertension (PAH)
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Injectable Agents for the Treatment of Pulmonary Arterial Hypertension (PAH) Clinical Edit Information Included in this Document
Dr Ian Roberts Oxford. Oxford Pathology Course 2010 for FRCPath Illustration-Cellular Pathology. Oxford Radcliffe NHS Trust
Dr Ian Roberts Oxford Oxford Pathology Course 2010 for FRCPath Present the basic diagnostic features of the commonest conditions causing proteinuria & haematuria Highlight diagnostic pitfalls Nephrotic
Lidoderm (Lidocaine) Patch
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
Ambulatory Blood Pressure Monitoring
Ambulatory Blood Pressure Monitoring and Devices Chapter.1 Enrollment..................................................................... -2.2 Benefits, Limitations, and Authorization Requirements...........................
FOLLOW-UP AFTER EMERGENCY DEPARTMENT VISIT FOR PEOPLE WITH HIGH-RISK MULTIPLE CHRONIC CONDITIONS (FMC) HEDIS (Administrative)
FOLLOW-UP AFTER EMERGENCY DEPARTMENT VISIT FOR PEOPLE WITH HIGH-RISK MULTIPLE CHRONIC CONDITIONS (FMC) APPLICATIONS OBJECTIVE Purpose of Measure: ELIGIBLE POPULATION Which members are included? STANDARD
Prior Authorization Opioid Overutilization 2017
Drugs Requiring Prior Authorization Label Name ACETAMINOPHEN/CAFFEINE/DIHYDROCODEINE CAPSULE ACETAMINOPHEN/CODEINE SOLUTION ACETAMINOPHEN/CODEINE TABLET ASCOMP/CODEINE CAPSULE BUTALBITAL/CAFFEINE/ACETAMINOPHEN/CODEINE
AMBULATORY BLOOD PRESSURE MONITORING AND DEVICES CSHCN SERVICES PROGRAM PROVIDER MANUAL
AMBULATORY BLOOD PRESSURE MONITORING AND DEVICES CSHCN SERVICES PROGRAM PROVIDER MANUAL FEBRUARY 2018 CSHCN PROVIDER PROCEDURES MANUAL FEBRUARY 2018 AMBULATORY B LOOD PRESSURE MONITORING AND DEVICES Table
Texas Prior Authorization Program Clinical Criteria
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Aldurazyme Adagen Carbaglu Ceprotin Elaprase Fabrazyme Lumizyme Naglazyme Orfandin Ravicti Vimizim Note: Click the hyperlink to navigate
ESRD Dialysis Prevalence - One Year Statistics
Age Group IL Other Total 00-04 12 1 13 05-09 5 2 7 10-14 15 1 16 15-19 55 2 57 20-24 170 10 180 25-29 269 14 283 30-34 381 9 390 35-39 583 14 597 40-44 871 20 891 45-49 1,119 20 1,139 50-54 1,505 35 1,540
Sample page. Urology/Nephrology. A comprehensive illustrated guide to coding and reimbursement CODING COMPANION
CODING COMPNION 2018 Urology/Nephrology comprehensive illustrated guide to coding and reimbursement POWER UP YOUR CODING with Optum360, your trusted coding partner for 32 years. Visit optum360coding.com.
Texas Prior Authorization Program Clinical Edit Criteria. H.P. Acthar
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
532.6 (chronic or unspecified duodenal
Supplementary table 1: ICD-9 and ICD-10 codes used for the identification of major bleeding and endoscopy Bleeding episode type ICD-9 codes ICD-10 codes Intracranial 430 (Subarachnoid), 431 (intracerebral),
Agents for the Treatment of Hepatitis C
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
A clinical syndrome, composed mainly of:
Nephritic syndrome We will discuss: 1)Nephritic syndrome: -Acute postinfectious (poststreptococcal) GN -IgA nephropathy -Hereditary nephritis 2)Rapidly progressive GN (RPGN) A clinical syndrome, composed
Texas Prior Authorization Program Clinical Edit Criteria
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Aldara 5% Cream Drugs requiring prior authorization: the list of drugs requiring
SPECIALISED SERVICES NATIONAL DEFINITIONS SET (THIRD EDITION 2008) Specialised Renal Services (adult) - Definition No. 11
SPECIALISED SERVICES NATIONAL DEFINITIONS SET (THIRD EDITION 2008) Specialised Renal Services (adult) - Definition No. 11 Preface This definition is part of the third edition of the Specialised Services
BETA-2 MICROGLOBULIN Test Code Test Name CPT
BETA-2 MICROGLOBULIN Test Code Test Name CPT BE2MC Beta-2 Microglobulin 82232 Narrative Description ICD9 ACUTE IN DISEASES CLASSIFIED ELSEWHERE 580.81 ACUTE WITH LESION OF PROLIFERATIVE 580.0 ACUTE WITH
Prof. Franco Ferrario Nephropathology Unit Department of Pathology San Gerardo Hospital Università Milan Bicocca Monza, Italy.
The role of repeated biopsies in the management of Lupus Nephritis Franco Ferrario, Milan, Italy Chairs: David Jayne, Cambridge, UK Vladimir Tesar, Prague, Czech Republic Prof. Franco Ferrario Nephropathology
Glomerular pathology in systemic disease
Glomerular pathology in systemic disease Lecture outline Lupus nephritis Diabetic nephropathy Glomerulonephritis Associated with Bacterial Endocarditis and Other Systemic Infections Henoch-Schonlein Purpura
Glucagon-Like Peptide (GLP-1) Receptor Agonists Clinical Edit Criteria
Glucagon-Like Peptide (GLP-1) Receptor Agonists Clinical Edit Criteria Drug/Drug Class: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Superior HealthPlan follows the guidance of the Texas Vendor Drug
Glomerular diseases mostly presenting with Nephritic syndrome
Glomerular diseases mostly presenting with Nephritic syndrome 1 The Nephritic Syndrome Pathogenesis: proliferation of the cells in glomeruli & leukocytic infiltrate Injured capillary walls escape of RBCs
Renal Pathology 1: Glomerulus. With many thanks to Elizabeth Angus PhD for EM photographs
Renal Pathology 1: Glomerulus With many thanks to Elizabeth Angus PhD for EM photographs Anatomy of the Kidney http://www.yalemedicalgroup.org/stw/page.asp?pageid=stw028980 The Nephron http://www.beltina.org/health-dictionary/nephron-function-kidney-definition.html
Glomerular Pathology- 1 Nephrotic Syndrome. Dr. Nisreen Abu Shahin
Glomerular Pathology- 1 Nephrotic Syndrome Dr. Nisreen Abu Shahin The Nephrotic Syndrome a clinical complex resulting from glomerular disease & includes the following: (1) massive proteinuria (3.5 gm /day
Drugs requiring prior authorization: the list of drugs requiring prior authorization for this clinical criteria
Drug/Drug Class Antipsychotics Clinical Criteria Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization for this clinical criteria Prior
CHAPTER 2. Primary Glomerulonephritis
2nd Report of the PRIMARY GLOMERULONEPHRITIS CHAPTER 2 Primary Glomerulonephritis Sunita Bavanandan Lee Han Wei Lim Soo Kun 21 PRIMARY GLOMERULONEPHRITIS 2nd Report of the 2.1 Introduction This chapter
Glomerular pathology-2 Nephritic syndrome. Dr. Nisreen Abu Shahin
Glomerular pathology-2 Nephritic syndrome Dr. Nisreen Abu Shahin 1 The Nephritic Syndrome Pathogenesis: inflammation proliferation of the cells in glomeruli & leukocytic infiltrate Injured capillary walls
Texas Prior Authorization Program Clinical Criteria
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Ketorolac Clinical Criteria Information Included in this Document Ketorolac Oral Drugs requiring prior authorization: the list of drugs
Clinical and pathological characteristics of patients with glomerular diseases at a university teaching hospital: 5-year prospective review
Clinical and pathological characteristics of patients with glomerular diseases at a university teaching hospital: 5-year prospective review KW Chan, TM Chan, IKP Cheng Objective. To examine the prevalence
Contractor Information. LCD Information. Local Coverage Determination (LCD): Retroperitoneal Ultrasound (L34577) Document Information
Local Coverage Determination (LCD): Retroperitoneal Ultrasound (L34577) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor Information Contractor
Case 3. ACCME/Disclosure. Laboratory results. Clinical history 4/13/2016
Case 3 Lynn D. Cornell, M.D. Mayo Clinic, Rochester, MN Cornell.Lynn@mayo.edu USCAP Renal Case Conference March 13, 2016 ACCME/Disclosure Dr. Cornell has nothing to disclose Clinical history 57-year-old
Texas Prior Authorization Program Clinical Edit Criteria
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
Texas Prior Authorization Program Clinical Criteria. Allergen Extracts
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Clinical Information Included in this Document Oralair (Mixed Grass Pollens Allergen Extract)) Drugs requiring prior authorization: the
Case Presentation Turki Al-Hussain, MD
Case Presentation Turki Al-Hussain, MD Director, Renal Pathology Chapter Saudi Society of Nephrology & Transplantation Consultant Nephropathologist & Urological Pathologist Department of Pathology & Laboratory
Texas Prior Authorization Program Clinical Edit Criteria
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Oral Drugs requiring prior authorization: the list of drugs requiring prior
Texas Prior Authorization Program Clinical Edit Criteria
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
Dr Ian Roberts Oxford. Oxford Pathology Course 2010 for FRCPath Illustration-Cellular Pathology. Oxford Radcliffe NHS Trust
Dr Ian Roberts Oxford Oxford Pathology Course 2010 for FRCPath Plan of attack: Diagnostic approach to the renal biopsy Differential diagnosis of the clinical syndromes of renal disease Microscopy Step
Xyrem (Sodium Oxybate)
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Clinical Criteria Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
Familial DDD associated with a gain-of-function mutation in complement C3.
Familial DDD associated with a gain-of-function mutation in complement C3. Santiago Rodríguez de Córdoba, Centro de investigaciones Biológicas, Madrid Valdés Cañedo F. and Vázquez- Martul E., Complejo
Drug Regimen Optimization
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Clinical Criteria Information Included in this Document Excluding Valsartan / Ramipril Prior authorization criteria logic: a description
Texas Prior Authorization Program Clinical Criteria
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Clinical Criteria Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website.
PROPOSED/DRAFT Local Coverage Determination (LCD): Retroperitoneal Ultrasound (DL34577) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Please note:
C1q nephropathy the Diverse Disease
C1q nephropathy the Diverse Disease Danica Galešić Ljubanović School of Medicine, University of Zagreb Dubrava University Hospital Zagreb, Croatia Definition Dominant or codominant ( 2+), mesangial staining
Lab 3, case 1. Is this an example of nephrotic or nephritic syndrome? Why? Which portion of the nephron would you expect to be abnormal?
Lab 3, case 1 12-year-old Costa Rican boy is brought into clinic by his parents because of dark brownish-red urine over the last 24 hours. The family has been visiting friends in Indianapolis for two weeks.
Index. electron microscopy, 81 immunofluorescence microscopy, 80 light microscopy, 80 Amyloidosis clinical setting, 185 etiology/pathogenesis,
A Acute antibody-mediated rejection (Acute AMR) clinical features, 203 clinicopathologic correlations, 206 pathogenesis, 205 206 204 205 light microscopy, 203 204 Acute cellular rejection (ACR) clinical
29th Annual Meeting of the Glomerular Disease Collaborative Network
29th Annual Meeting of the Glomerular Disease Collaborative Network Updates on the Pathogenesis IgA Nephropathy and IgA Vasculitis (HSP) J. Charles Jennette, M.D. Brinkhous Distinguished Professor and
CHAPTER 2 PRIMARY GLOMERULONEPHRITIS
CHAPTER 2 Sunita Bavanandan Lim Soo Kun 19 5th Report of the 2.1: Introduction This chapter covers the main primary glomerulonephritis that were reported to the MRRB from the years 2005-2012. Minimal change
Sildenafil / Tadalafil
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Sildenafil / Tadalafil Clinical Criteria Information Included in this Document Drugs requiring prior authorization: the list of drugs
Benchmark Pay for Performance Program Guidelines Program Year
Benchmark Pay for Performance Program Guidelines 2018 Program Year 2 Panel Engagement Table of Contents General Program Guidelines... 4 Program Overview... 4 Provider Participation Eligibility... 4 Reports...
Complement in vasculitis and glomerulonephritis. Andy Rees Clinical Institute of Pathology Medical University of Vienna
Complement in vasculitis and glomerulonephritis Andy Rees Clinical Institute of Pathology Medical University of Vienna 41 st Heidelberg Nephrology Seminar March 2017 The complement system An evolutionary
29 Glomerular disease: an overview
29 Glomerular : an overview Renal Extra-renal Neurological changes Clinical syndromes pressure Sore throat (streptococcal) Rash Cardiac valve lesions Hemoptysis Asymptomatic or Acute Glomerulonephritis
Classification of Glomerular Diseases and Defining Individual Glomerular Lesions: Developing International Consensus
Classification of Glomerular Diseases and Defining Individual Glomerular Lesions: Developing International Consensus Mark Haas MD, PhD Department of Pathology & Laboratory Medicine Cedars-Sinai Medical
Texas Prior Authorization Program Clinical Edit Criteria
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Growth Hormone Clinical Edit Information Included in this Document Excluding Serostim / Zorbtive Serostim Drugs requiring prior
Texas Prior Authorization Program Clinical Criteria. Revisions were recommended by MCOs and VDP to ensure appropriate utilization.
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Growth Hormone Revisions were recommended by MCOs and VDP to ensure appropriate utilization. Clinical PA Information Included in this
C3 GLOMERULOPATHIES. Budapest Nephrology School Zoltan Laszik
C3 GLOMERULOPATHIES Budapest Nephrology School 8.30.2018. Zoltan Laszik 1 Learning Objectives Familiarize with the pathogenetic mechanisms of glomerular diseases Learn the pathologic landscape and clinical
PATTERNS OF RENAL INJURY
PATTERNS OF RENAL INJURY Normal glomerulus podocyte Glomerular capillaries electron micrograph THE CLINICAL SYNDROMES 1. The Nephrotic Syndrome 2. The Acute Nephritic Syndrome 3. Rapidly Progressive Glomerulonephritis
GOODPASTURE'S SYNDROME WITH CONCOMITANT IMMUNE COMPLEX MIXED MEMBRANOUS AND PROLIFERATIVE GLOMERULONEFRITIS
GOODPASTURE'S SYNDROME WITH CONCOMITANT IMMUNE COMPLEX MIXED MEMBRANOUS AND PROLIFERATIVE GLOMERULONEFRITIS VESNA JURČIĆ 1, ANDREJA ALEŠ RIGLER 2, INSTITUTE OF PATHOLOGY, FACULTY OF MEDICINE, UNIVERSITY
CHAPTER 4. Paediatric Renal Biopsies
2nd Report of the Malaysian Registry of Renal Biopsy 2008 PAEDIATRIC RENAL BIOPSIES CHAPTER 4 Paediatric Renal Biopsies Lee Ming Lee Lim Yam Ngo Lynster Liaw Susan Pee Wan Jazilah Wan Ismail Yap Yok Chin
Chapter 1. Incidence of End Stage Kidney Disease. Contents:
Chapter 1 Incidence of End Stage Kidney Disease Contents: Incidence of End Stage Kidney Disease 1-1 Stock and Flow 1-2 Incident patients 1-3 Incident Rates 1-3 Late Referral 1-7 Co-Morbidities 1-9 Primary
Mayo Clinic/ RPS Consensus Report on Classification, Diagnosis, and Reporting of Glomerulonephritis
Mayo Clinic/ RPS Consensus Report on Classification, Diagnosis, and Reporting of Glomerulonephritis Sanjeev Sethi, MD, PhD Department of Laboratory Medicine and Pathology Disclosure Relevant Financial
Case # 2 3/27/2017. Disclosure of Relevant Financial Relationships. Clinical history. Clinical history. Laboratory findings
Case # 2 Christopher Larsen, MD Arkana Laboratories Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education Committee) in a position to influence or control the content
Growth Hormone Excluding Serostim / Zorbtive
Drugs Requiring Prior Authorization *RESTRICTED PHARMACY NETWORK APPLIES See Prior Authorization Forms or contact Navitus Customer Care at 1-877-908-6023 for details. Label Name GCN *GENOTROPIN 12 MG CARTRIDGE
Year 2004 Paper one: Questions supplied by Megan
QUESTION 53 Endothelial cell pathology on renal biopsy is most characteristic of which one of the following diagnoses? A. Pre-eclampsia B. Haemolytic uraemic syndrome C. Lupus nephritis D. Immunoglobulin
URINE CULTURE, BACTERIAL
A02.1 Salmonella sepsis A18.14 Tuberculosis of prostate A34 Obstetrical tetanus A40.0 Sepsis due to streptococcus, group A A40.1 Sepsis due to streptococcus, group B A40.3 Sepsis due to Streptococcus pneumoniae
Agents for Cystic Fibrosis
Texas Prior Authorization Program Clinical Edit Criteria Clinical Edit Information Included in this Document Kalydeco (Ivacaftor) Drugs requiring prior authorization: the list of drugs requiring prior
Chapter 8: ESRD Among Children, Adolescents, and Young Adults
Chapter 8: ESRD Among Children, Adolescents, and Young Adults The number of children beginning end-stage renal disease (ESRD) care decreased by 6% in 2014, totaling 1,398 (Figure 8.1.a). 9,721 children
Texas Prior Authorization Program Clinical Edit Criteria
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
Icd 10 code for end stage liver disease. Pinni Meedha Mojutho Ammanu Dengina Koduku Part 1 Kama Kathalu
Search for: Search Search Icd 10 code for end stage liver disease Pinni Meedha Mojutho Ammanu Dengina Koduku Part 1 Kama Kathalu Medical uses Malignancy. Radical cystectomy is the recommended treatment
Glomerulonephritis. Dr Rodney Itaki Anatomical Pathology Discipline.
Glomerulonephritis Dr Rodney Itaki Anatomical Pathology Discipline. University of Papua New Guinea School of Medicine & Health Sciences Division of Pathology Gross anatomy Ref: Goggle Images Microanatomy
N. Hiramatsu, T. Kuroiwa, H. Ikeuchi, A. Maeshima, Y. Kaneko, K. Hiromura, K. Ueki and Y. Nojima
Rheumatology 28;47:72 77 Advance Access publication 4 April 28 doi:1.193/rheumatology/ken19 Revised classification of lupus nephritis is valuable in predicting renal outcome with an indication of the proportion
USRDS UNITED STATES RENAL DATA SYSTEM
USRDS UNITED STATES RENAL DATA SYSTEM Chapter 8: Pediatric ESRD 1,462 children in the United States began end-stage renal disease (ESRD) care in 2013. 9,921 children were being treated for ESRD on December
Approach to Glomerular Diseases: Clinical Presentation Nephrotic Syndrome Nephritis
GLOMERULONEPHRITIDES Vivette D Agati Jai Radhakrishnan Approach to Glomerular Diseases: Clinical Presentation Nephrotic Syndrome Nephritis Heavy Proteinuria Renal failure Low serum Albumin Hypertension
S2 File. Clinical Classifications Software (CCS). The CCS is a
S2 File. Clinical Classifications Software (CCS). The CCS is a diagnosis categorization scheme based on the ICD-9-CM that aggregates all diagnosis codes into 262 mutually exclusive, clinically homogeneous
NEPHRITIC SYNDROME. By Dr Mai inbiek
NEPHRITIC SYNDROME By Dr Mai inbiek Nephritic Syndrome The nephritic Syndrome is a clinical complex, usually of acute onset. Is caused by inflammatory lesions of glomeruli. Characterized by; 1) Hematuria